Nycomed announces offer to purchase Senior Notes

15.11.2006Nycomed today announced an offer to purchase and consent solicitation for any and all of its 11.50% Senior Notes due 2013 and any and all of its 11.75% PIK Notes due 2013. The consent deadline for the offer to purchase is 30 November 2006 and the offer to purchase expires on 21 December 2006, unless extended or terminated. The offer to purchase is conditional upon, among other things, the completion of the ALTANA Pharma acquisition and the related financing.

Settlement is expected to occur on 29 December 2006.

The offer to purchase outstanding bond issues is in line with the refinancing of existing debt and the acquisition of ALTANA Pharma where Nycomed, as previously announced, has commenced the syndication of its new € 5.7 billion senior credit facilities.


About Nycomed

Nycomed is a pharmaceutical company dedicated to meeting needs in Europe. The company provides hospital products throughout the region and general practitioner and pharmacy medicines in selected markets.

New products are sourced through licensing agreements with research companies. Here Nycomed provides late-stage clinical development, registration and marketing.

Headquartered in Roskilde, Denmark, the company employs about 3,500 people throughout Europe and Russia-CIS. Nycomed is privately owned and had a 2005 revenue of € 747.5 million.

For more information visit www.nycomed.com


For further information

Runar Bjørklund, CFO
Phone: +45 46 77 11 11
Mobile: +45 22 41 12 27

Christian Seidelin, VP Corporate Finance
Phone: +45 46 77 11 11
Mobile: +45 20 40 70 72

 

 

For further information

Media:
General phone:

+41 44 555 15 10
Beatrix Benz,

phone: +41 44 555 1508
Tobias Cottmann,

phone: +41 44 555 1501

Investors:
Christian B. Seidelin,

phone: +41 44 555 11 04

Related information


English PDF
Danish PDF

Top of page

Takeda Pharma